Healthcare in the future
Combining medical data
Innovation in clinical research
Janssen aims to pursue sustainable economic growth. The company wants to be a ‘transformational medical innovator’ focusing on the development of innovative therapeutic solutions for unfulfilled medical needs. The company concentrates its efforts on five research fields to be able to make a real difference to the health of the population worldwide.
Janssen is convinced that strong corporate results, correct policies and focused activities pave the way towards economic sustainability. Janssen is convinced that strong corporate results, correct policies and focused activities pave the way towards economic sustainability.With its long-term healthcare vision the company is working on sustainable, affordable and accessible care, while accepting its responsibilities and calling upon all stakeholders to together prepare for the future.
The healthcare landscape offers opportunities and challenges which the company has cast into a vision of healthcare in the future.
The healthcare landscape offers opportunities and challenges which the company has cast into a vision of healthcare in the future. We are evolving from the traditional, reactive healthcare paradigm to a new era of preventive and personalized healthcare. More and more resources are becoming available to detect diseases, to treat them and follow them up. Curative medicines will only remain as one part of the solution. Janssen is accordingly preparing for broader care for the patient and a new care model for prevention, diagnosis, treatment and follow-up. The focus here is on the patient and his or her personal needs.
Numerous sectors play a vital, complementary role with the creation of this new care model. There will be very many more partners involved in the field of equipment, software, components and healthcare than today. This is why Janssen throws open the doors with its open innovation model: in search of a shared basis with large companies from other branches of industry, but equally with the academic world, SMEs and government institutions. In 2013 Janssen concluded a variety of strategic partnerships and created synergies with the complementary skills of each party. The future depends on the collation of the knowledge present across the whole the world. Only then can the company come up with ever-increasingly innovative solutions.
The biopharmaceutical industry in Belgium is among the absolute world leaders today. This is partly due to Belgian policy-makers. Over the past ten years Belgium has indeed made efforts to create an attractive environment for pharmaceutical investments. These efforts have been amply rewarded. The biopharmaceutical industry has developed to become an essential mainstay of the Belgian economy. As a company with deep roots in Belgium, today Janssen wants to continue contributing to the Belgian economy and employment with a far-reaching investment policy. Although the economic climate has created difficult challenges for Janssen, the company is convinced it has the potential to contribute to further sustainable growth